Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference

The new mini-textbook by Kamps & Hoffmann
PDF, 110 pages


  Colorectal Neoplasms

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    March 2020
  1. ZLOBEC I, Dawson HE, Blank A, Bokhorst JM, et al
    Are tumour grade and tumour budding equivalent in colorectal cancer? A retrospective analysis of 771 patients.
    Eur J Cancer. 2020;130:139-145.
    PubMed     Text format     Abstract available


  2. KLINKHAMMER-SCHALKE M, Steinger B, Koller M, Zeman F, et al
    Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer.
    Eur J Cancer. 2020;130:102-113.
    PubMed     Text format     Abstract available


  3. COHEN R, Vernerey D, Bellera C, Meurisse A, et al
    Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
    Eur J Cancer. 2020;130:63-71.
    PubMed     Text format     Abstract available


  4. KIM JW, Han SW, Cho JY, Chung IJ, et al
    Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial.
    Eur J Cancer. 2020;130:51-62.
    PubMed     Text format     Abstract available


    February 2020
  5. LUQUE-FERNANDEZ MA, Goncalves K, Salamanca-Fernandez E, Redondo-Sanchez D, et al
    Multimorbidity and short-term overall mortality among colorectal cancer patients in Spain: A population-based cohort study.
    Eur J Cancer. 2020;129:4-14.
    PubMed     Text format     Abstract available


    January 2020
  6. BHARDWAJ M, Weigl K, Tikk K, Holland-Letz T, et al
    Multiplex quantitation of 270 plasma protein markers to identify a signature for early detection of colorectal cancer.
    Eur J Cancer. 2020;127:30-40.
    PubMed     Text format     Abstract available


  7. FASTNER G, Sedlmayer F, Widder J, Metz M, et al
    Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.
    Eur J Cancer. 2020;127:12-20.
    PubMed     Text format     Abstract available


  8. GINI A, Jansen EEL, Zielonke N, Meester RGS, et al
    Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review.
    Eur J Cancer. 2020 Jan 10. pii: S0959-8049(19)30870.
    PubMed     Text format     Abstract available


    November 2019
  9. SUMMERS MG, Maughan TS, Kaplan R, Law PJ, et al
    Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
    Eur J Cancer. 2019;124:56-63.
    PubMed     Text format     Abstract available


  10. DUCREUX M, Petersen LN, Ohler L, Bergamo F, et al
    Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Eur J Cancer. 2019;123:146-154.
    PubMed     Text format     Abstract available


    October 2019
  11. SOLDEVILLA B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, et al
    The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Eur J Cancer. 2019;123:118-129.
    PubMed     Text format     Abstract available


    August 2019
  12. MUNEMOTO Y, Nakamura M, Takahashi M, Kotaka M, et al
    SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    Eur J Cancer. 2019;119:158-167.
    PubMed     Text format     Abstract available


  13. GALLOIS C, Artru P, Lievre A, Auclin E, et al
    Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study.
    Eur J Cancer. 2019;119:35-43.
    PubMed     Text format     Abstract available


    July 2019
  14. LOUPAKIS F, Intini R, Cremolini C, Orlandi A, et al
    A validated prognostic classifier for (V600E)BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.
    Eur J Cancer. 2019;118:121-130.
    PubMed     Text format     Abstract available


  15. MILANO G
    More rationale for optimal sequencing of therapeutic monoclonal antibodies in metastatic colorectal cancer.
    Eur J Cancer. 2019;117:131-132.
    PubMed     Text format    


    June 2019
  16. BROUWER NPM, Heil TC, Olde Rikkert MGM, Lemmens VEPP, et al
    The gap in postoperative outcome between older and younger patients with stage I-III colorectal cancer has been bridged; results from the Netherlands cancer registry.
    Eur J Cancer. 2019;116:1-9.
    PubMed     Text format     Abstract available


    May 2019
  17. VAUGHAN-SHAW PG, Zgaga L, Theodoratou E, Blackmur JP, et al
    Whether vitamin D supplementation protects against colorectal cancer risk remains an open question.
    Eur J Cancer. 2019;115:1-3.
    PubMed     Text format    


    March 2019
  18. ARGILES G, Andre T, Hollebecque A, Calvo A, et al
    Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Eur J Cancer. 2019;112:12-19.
    PubMed     Text format     Abstract available


  19. PUCCINI A, Loupakis F, Stintzing S, Cao S, et al
    Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.
    Eur J Cancer. 2019;111:138-147.
    PubMed     Text format     Abstract available


    February 2019
  20. KOSUMI K, Hamada T, Zhang S, Liu L, et al
    Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Eur J Cancer. 2019;111:82-93.
    PubMed     Text format     Abstract available


  21. CASCINU S, Poli D, Zaniboni A, Lonardi S, et al
    The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
    Eur J Cancer. 2019;111:1-7.
    PubMed     Text format     Abstract available


  22. CREMOLINI C, Marmorino F, Bergamo F, Aprile G, et al
    Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
    Eur J Cancer. 2019;109:175-182.
    PubMed     Text format     Abstract available


    January 2019
  23. MODEST DP, Pant S, Sartore-Bianchi A
    Treatment sequencing in metastatic colorectal cancer.
    Eur J Cancer. 2019;109:70-83.
    PubMed     Text format     Abstract available


    December 2018
  24. SCHWARTZ S, Szeto C, Tian Y, Cecchi F, et al
    Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Eur J Cancer. 2018;107:164-174.
    PubMed     Text format     Abstract available


  25. SUENAGA M, Stintzing S, Cao S, Zhang W, et al
    Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
    Eur J Cancer. 2018;107:100-114.
    PubMed     Text format     Abstract available


    November 2018
  26. HOLCH JW, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Eur J Cancer. 2018;106:115-125.
    PubMed     Text format     Abstract available


  27. BARANISKIN A, Buchberger B, Pox C, Graeven U, et al
    Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2018;106:37-44.
    PubMed     Text format     Abstract available


  28. IMANISHI M, Yamamoto Y, Hamano Y, Yamada T, et al
    Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.
    Eur J Cancer. 2018;106:69-77.
    PubMed     Text format     Abstract available


    October 2018
  29. MOLOGNI L
    Synergistic activity of dasatinib in combination with beta-catenin blockade in colorectal cancer cells.
    Eur J Cancer. 2018 Oct 12. pii: S0959-8049(18)31366.
    PubMed     Text format    


    September 2018
  30. SALEM ME, Yin J, Weinberg BA, Renfro LA, et al
    Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD dat
    Eur J Cancer. 2018;103:205-213.
    PubMed     Text format     Abstract available


  31. LORD AC, D'Souza N, Pucher PH, Moran BJ, et al
    Author response to comment on 'significance of extranodal tumour deposits in colorectal cancer: A systematic review and meta-analysis'.
    Eur J Cancer. 2018 Sep 25. pii: S0959-8049(18)31336.
    PubMed     Text format    


  32. GOOTJES EC, Bakkerus L, Ten Tije AJ, Witteveen PO, et al
    The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer.
    Eur J Cancer. 2018;103:160-164.
    PubMed     Text format     Abstract available


  33. HAMADA T, Liu L, Nowak JA, Mima K, et al
    Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour.
    Eur J Cancer. 2018;103:98-107.
    PubMed     Text format     Abstract available


  34. HIRST Y, Stoffel S, Baio G, McGregor L, et al
    Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out.
    Eur J Cancer. 2018 Sep 6. pii: S0959-8049(18)31120.
    PubMed     Text format     Abstract available


    August 2018
  35. MADI A, Fisher D, Maughan TS, Colley JP, et al
    Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    Eur J Cancer. 2018;102:31-39.
    PubMed     Text format     Abstract available


  36. TEJPAR S, Yan P, Piessevaux H, Dietrich D, et al
    Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Eur J Cancer. 2018;99:66-77.
    PubMed     Text format     Abstract available


    July 2018
  37. ARANDA E, Garcia Alfonso P, Benavides M, Sanchez Ruiz A, et al
    First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    Eur J Cancer. 2018 Jul 24. pii: S0959-8049(18)30938.
    PubMed     Text format     Abstract available


  38. HEGEWISCH-BECKER S, Nopel-Dunnebacke S, Hinke A, Graeven U, et al
    Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
    Eur J Cancer. 2018;101:105-113.
    PubMed     Text format     Abstract available


  39. GELLI M, Huguenin JFL, de Baere T, Benhaim L, et al
    Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?
    Eur J Cancer. 2018;100:94-103.
    PubMed     Text format     Abstract available


    June 2018
  40. GOEY KKH, Sorbye H, Glimelius B, Adams RA, et al
    Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
    Eur J Cancer. 2018;100:35-45.
    PubMed     Text format     Abstract available


  41. STOCKER G, Hacker UT, Fiteni F, John Mahachie J, et al
    Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
    Eur J Cancer. 2018;99:49-57.
    PubMed     Text format     Abstract available


    May 2018
  42. APARICIO T, Ducreux M, Faroux R, Barbier E, et al
    Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
    Eur J Cancer. 2018;98:1-9.
    PubMed     Text format     Abstract available


  43. APARICIO T, Bouche O, Francois E, Retornaz F, et al
    Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
    Eur J Cancer. 2018;97:16-24.
    PubMed     Text format     Abstract available


  44. AUCLIN E, Andre T, Taieb J, Benetkiewicz M, et al
    Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments.
    Eur J Cancer. 2018 May 3. pii: S0959-8049(18)30782.
    PubMed     Text format    


  45. GOEY KKH, Mahmoud R, Sorbye H, Glimelius B, et al
    Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.
    Eur J Cancer. 2018;96:115-124.
    PubMed     Text format     Abstract available


    April 2018
  46. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Eur J Cancer. 2018;96:105-110.
    PubMed     Text format     Abstract available


  47. MATSUDA C, Ishiguro M, Teramukai S, Kajiwara Y, et al
    A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
    Eur J Cancer. 2018;96:54-63.
    PubMed     Text format     Abstract available


    March 2018
  48. TACHON G, Frouin E, Karayan-Tapon L, Auriault ML, et al
    Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.
    Eur J Cancer. 2018 Mar 5. pii: S0959-8049(18)30121.
    PubMed     Text format    


  49. MARGALIT O, Mamtani R, Yang YX, Reiss KA, et al
    Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer.
    Eur J Cancer. 2018;94:1-5.
    PubMed     Text format     Abstract available


  50. OGURA A, Akiyoshi T, Yamamoto N, Kawachi H, et al
    Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
    Eur J Cancer. 2018;91:11-20.
    PubMed     Text format     Abstract available


    February 2018
  51. YOSHINO T, Hsu Y, Nasroulah F
    Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
    Eur J Cancer. 2018 Feb 9. pii: S0959-8049(18)30084.
    PubMed     Text format    


  52. ZOU D, Lou J, Ke J, Mei S, et al
    Integrative expression quantitative trait locus-based analysis of colorectal cancer identified a functional polymorphism regulating SLC22A5 expression.
    Eur J Cancer. 2018;93:1-9.
    PubMed     Text format     Abstract available


    January 2018
  53. VAN ROOIJEN KL, Shi Q, Goey KKH, Meyers J, et al
    Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database.
    Eur J Cancer. 2018;91:99-106.
    PubMed     Text format     Abstract available


  54. IBRAHIM S, Raoul W, Lecomte T, Paintaud G, et al
    Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab.
    Eur J Cancer. 2018 Jan 9. pii: S0959-8049(17)31461.
    PubMed     Text format    


  55. VON MOOS R, Koeberle D, Schacher S, Hayoz S, et al
    Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
    Eur J Cancer. 2018;89:82-89.
    PubMed     Text format     Abstract available


  56. SWETS M, Kuppen PJK, Blok EJ, Gelderblom H, et al
    Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy?
    Eur J Cancer. 2018;89:1-8.
    PubMed     Text format     Abstract available


    December 2017
  57. VAN CUTSEM E, Mayer RJ, Laurent S, Winkler R, et al
    The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Eur J Cancer. 2017;90:63-72.
    PubMed     Text format     Abstract available


    November 2017
  58. MODEST DP, Denecke T, Pratschke J, Ricard I, et al
    Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    Eur J Cancer. 2017;88:77-86.
    PubMed     Text format     Abstract available


  59. COHEN R, Buhard O, Cervera P, Hain E, et al
    Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Eur J Cancer. 2017;86:266-274.
    PubMed     Text format     Abstract available


    October 2017
  60. SUENAGA M, Schirripa M, Cao S, Zhang W, et al
    Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
    Eur J Cancer. 2017;86:197-206.
    PubMed     Text format     Abstract available


  61. KEIKES L, Koopman M, Tanis PJ, Lemmens VEPP, et al
    Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review.
    Eur J Cancer. 2017;86:166-177.
    PubMed     Text format     Abstract available


  62. PREVOSTEL C, Blache P
    The dose-dependent effect of SOX9 and its incidence in colorectal cancer.
    Eur J Cancer. 2017;86:150-157.
    PubMed     Text format     Abstract available


  63. MALKA D, Rotolo F, Boige V
    First-line treatment in metastatic colorectal cancer: Important or crucial?
    Eur J Cancer. 2017;84:363-366.
    PubMed     Text format    


    September 2017
  64. TURATI F, Bravi F, Di Maso M, Bosetti C, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and colorectal cancer risk.
    Eur J Cancer. 2017;85:86-94.
    PubMed     Text format     Abstract available


    August 2017
  65. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    PubMed     Text format    


    January 2017
  66. CHAN AK, Siriwardena AK
    Management of synchronous liver metastases and the recommendations of the second St. Gallen European Organisation for Research and Treatment of Cancer consensus conference on the management of rectal cancer.
    Eur J Cancer. 2017;71:51-52.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: